Key result
Heart failure with reduced ejection fraction has seen significant therapeutic advancements, evolving from digitalis and diuretics to neurohormonal inhibitors, device therapies, and SGLT2 inhibitors.
Answers are grounded in this paper and cite their sources.
This editorial reviews the historical evolution and current therapeutic implications of heart failure with reduced ejection fraction (HFrEF) treatments, from digitalis to SGLT2 inhibitors.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bello et al. (2020) conducted an editorial in Heart failure with reduced ejection fraction (HFrEF). Heart failure therapies (pharmacological and device-based) was evaluated. Heart failure with reduced ejection fraction has seen significant therapeutic advancements, evolving from digitalis and diuretics to neurohormonal inhibitors, device therapies, and SGLT2 inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: